{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:09Z","timestamp":1791207309121,"version":"4.1.0"},"reference-count":90,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1080\/10428190701713689","type":"journal-article","created":{"date-parts":[[2008,1,17]],"date-time":"2008-01-17T07:18:01Z","timestamp":1200554281000},"page":"19-26","source":"Crossref","is-referenced-by-count":77,"title":["Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia"],"prefix":"10.1080","volume":"49","author":[{"given":"Shaoguang","family":"Li","sequence":"first","affiliation":[{"name":"The Jackson Laboratory, Bar Harbor, ME, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2009,7]]},"reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/344251a0"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.10.3780"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810133191506"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2147"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2004.03.001"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.1089.1089"},{"issue":"18","key":"e_1_3_1_10_1","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/jco.2006.24.18_suppl.6506","article-title":"Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study","volume":"24","author":"Druker B J","year":"2006","unstructured":"Druker B J, Guilhot F, O'Brien S, Larson N, on behalf of the IRIS (International Randomized IF). Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): the 5-year update from the IRIS study. J Clin Oncol 2006; 24(Suppl 18S)6506","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3530"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"e_1_3_1_15_1","first-page":"3369","article-title":"High dose imatinib (STI571, Gleevec) provides durable long-term outcomes for patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC): follow-up of the phase II studies","volume":"102","author":"Talpaz M","year":"2003","unstructured":"Talpaz M, Goldman J, Sawyers C, Hochhaus A, Silver R T, Smith B D, et al. High dose imatinib (STI571, Gleevec) provides durable long-term outcomes for patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) or myeloid blast crisis (BC): follow-up of the phase II studies. Blood 2003; 102: 3369","journal-title":"Blood"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.319"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(00)00142-9"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.52.33260"},{"key":"e_1_3_1_19_1","first-page":"3589","article-title":"Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells","volume":"56","author":"Danhauser-Riedl S","year":"1996","unstructured":"Danhauser-Riedl S, Warmuth M, Druker B J, Emmerich B, Hallek M. Activation of Src kinases p53\/56lyn and p59hck by p210bcr\/abl in myeloid cells. Cancer Res 1996; 56: 3589\u20133596","journal-title":"Cancer Res"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401429"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C000126200"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.2.690"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M402290200"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606509103"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1127"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1343"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-1484"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.1087.1087"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009148847"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2408149"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.10.005"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1994.tb06319.x"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.22.12804"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/328342a0"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.8.2038.2038"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.7.2084"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(01)00357-4"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4732"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208081"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.9.2.329"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033454126"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.10.15.1845"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.7.10.3394-3401.1987"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.139.1.123"},{"key":"e_1_3_1_45_1","first-page":"317","article-title":"Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle","volume":"5","author":"Anderson S M","year":"1990","unstructured":"Anderson S M, Carroll P M, Lee F D. Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle. Oncogene 1990; 5: 317\u2013325","journal-title":"Oncogene"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.10.8.4365-4369.1990"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.3.6.827"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M605902200"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206008"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.11.3884-3896.2003"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf562"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020519"},{"key":"e_1_3_1_53_1","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1182\/blood.V93.12.4154","article-title":"Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation","volume":"93","author":"Ilaria R L","year":"1999","unstructured":"Ilaria R L, Jr, Hawley R G, Van Etten R A. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 1999; 93: 4154\u20134166","journal-title":"Blood"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/18.17.4754"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.14.2.232"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0288"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.20.6151"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0181"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403426"},{"key":"e_1_3_1_61_1","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar B","year":"2002","unstructured":"Nagar B, Bornmann W G, Pellicena P, Schindler T, Veach D R, Miller W T, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236\u20134243","journal-title":"Cancer Res"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.289.5486.1938"},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(03)00190-9"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1114"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403416"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03256446"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-12-200612190-00008"},{"key":"e_1_3_1_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_3_1_69_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_3_1_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_3_1_71_1","first-page":"159","article-title":"BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo","volume":"46","author":"Lee F Y","year":"2005","unstructured":"Lee F Y, Lombardo L, Camuso A, Castaneda S, Fager K, Flefleh C, et al. BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proc Am Assoc Cancer Res 2005; 46: 159, (abstr. 675)","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_3_1_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1731"},{"key":"e_1_3_1_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2050"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_3_1_76_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1182\/blood.V108.11.164.164","article-title":"Efficacy of dasatinib (SPRYCEL) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 START-C phase II study","volume":"108","author":"Baccarani M","year":"2006","unstructured":"Baccarani M, Kantarjian H M, Apperley J F, Lipton J H, Druker B, Countouriotis A, et al. Efficacy of dasatinib (SPRYCEL) in patients (pts) with chronic phase chronic myelogenous leukemia (CP-CML) resistant to or intolerant of imatinib: updated results of the CA180013 START-C phase II study. Blood 2006; 108(Suppl.)164","journal-title":"Blood"},{"key":"e_1_3_1_77_1","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1182\/blood.V108.11.2160.2160","article-title":"Dasatinib (SPRYCEL) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): updated results of the CA180-005 START-A phase II study","volume":"108","author":"Cortes J","year":"2006","unstructured":"Cortes J, Kim D W, Guilhot F, Rosti G, Silver R T, Gollerkeri A, et al. Dasatinib (SPRYCEL) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or -intolerant (im-i): updated results of the CA180-005 START-A phase II study. Blood 2006; 108(Suppl.)2160","journal-title":"Blood"},{"key":"e_1_3_1_78_1","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/blood.V108.11.745.745","article-title":"Dasatinib (SPRYCEL) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (im-r) or -intolerant (im-i)","volume":"108","author":"Martinelli G","year":"2006","unstructured":"Martinelli G, Hochhaus A, Coutre S, Apperley J F, Shah N, Gollerkeri A, et al. Dasatinib (SPRYCEL) efficacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (im-r) or -intolerant (im-i). Blood 2006; 108(Suppl.)745","journal-title":"Blood"},{"key":"e_1_3_1_79_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood.V108.11.286.286","article-title":"Dasatinib (SPRYCEL) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or -intolerant (im-i): updated results from the CA180-015 START-L study","volume":"108","author":"Dombret H","year":"2006","unstructured":"Dombret H, Ottman O G, Rosti G, Simonsson B, Larson R A, Gollerkeri A, et al. Dasatinib (SPRYCEL) in patients (pts) with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant (im-r) or -intolerant (im-i): updated results from the CA180-015 START-L study. Blood 2006; 108(Suppl.)286","journal-title":"Blood"},{"key":"e_1_3_1_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-056028"},{"issue":"18","key":"e_1_3_1_81_1","doi-asserted-by":"crossref","first-page":"7023","DOI":"10.1200\/jco.2007.25.18_suppl.7023","article-title":"Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations","volume":"25","author":"Hochhaus A","year":"2007","unstructured":"Hochhaus A, Branford S, Radich J, Mueller M C, Shah N, Erben P, et al. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. J Clin Oncol 2007; 25(Suppl 18S)7023","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035493"},{"issue":"18","key":"e_1_3_1_83_1","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1200\/jco.2007.25.18_suppl.7040","article-title":"A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed\/refractory Ph+ acute lymphoblastic leukemia (ALL)","volume":"25","author":"Larson R","year":"2007","unstructured":"Larson R, Ottmann O, Kantarjian H, le Coutre P, Baccarani M, Weitzman A, et al. A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed\/refractory Ph+ acute lymphoblastic leukemia (ALL). J Clin Oncol 2007; 25(Suppl 18S)7040","journal-title":"J Clin Oncol"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068073"},{"key":"e_1_3_1_85_1","first-page":"2177","article-title":"Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-\u03b1: follow-up results","volume":"8","author":"Kantarjian H M","year":"2002","unstructured":"Kantarjian H M, Talpaz M, O'Brien S, Smith T L, Giles F J, Faderl S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-\u03b1: follow-up results. Clin Cancer Res 2002; 8: 2177\u20132187","journal-title":"Clin Cancer Res"},{"key":"e_1_3_1_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011115)92:10<2501::AID-CNCR1600>3.0.CO;2-N"},{"key":"e_1_3_1_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402996"},{"key":"e_1_3_1_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1035-3"},{"key":"e_1_3_1_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0925"},{"key":"e_1_3_1_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403158"},{"issue":"1","key":"e_1_3_1_91_1","first-page":"0360","article-title":"Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP)","volume":"92","author":"Quintas-Cardama A","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, O'Brien S, Jones D, Borthakur G, Nicaise C, et al. Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP). Haematologica 2007; 92(Suppl 1)0360","journal-title":"Haematologica"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428190701713689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:27:19Z","timestamp":1770391639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428190701713689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1080\/10428190701713689"],"URL":"https:\/\/doi.org\/10.1080\/10428190701713689","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}